
To own Xylem, you need to believe that long term spending on water infrastructure, smart metering and outsourced treatment work will keep building a large, visible project pipeline. The recent print reinforces that story on profitability, with earnings per share from continuing operations at US$1.25 in the quarter and US$3.14 to US$3.15 over nine months, even as revenue guidance tightens.
The near term swing factor now sits around execution on that US$5.3b backlog and margin delivery, rather than top line momentum. This is because 2026 revenue is guided to about US$8.95b and flat organically. The clearest risk remains timing and scope of capital projects, especially if delays in utilities or industrial customers extend and slow conversion of contracted work into sales.
The guidance cut on reported revenue for 2026 is the key update for this catalyst mix, because it leans more weight onto mix, smart metering traction and cost work to sustain earnings quality. Management now expects sales of roughly US$8.95b, which implies reported revenue 1% lower year over year and organic performance that is flat.
For you, that ties directly back to the big drivers highlighted earlier, including smart metering growth and outsourced water contracts that skew toward higher margin and recurring earnings. If project decisions slip again or portfolio simplification around the 80/20 program disrupts operations, the risk is that near term earnings delivery tightens even if the long duration contracts stay intact.
Xylem's narrative projects US$10.4b revenue and US$1.5b earnings by 2029. That scenario assumes revenue grows by 4.6% a year and earnings rise by about US$0.5b from US$1.0b today.
Discover why Xylem's fair value currently indicates a 34% potential upside to its current price, which could narrow quickly.
One alternate view on Xylem focuses on contract risk. The most pessimistic analysts worry that long duration water deals and acquisitions could strain execution, so they were only pencilling in about US$9.6b of revenue and US$1.2b of earnings by 2029. That is a much harsher story. Use this earnings reset to compare those expectations with your own and see where your view fits along that spectrum.
Explore 5 other Xylem fair value estimates, including one that suggests there may be as much as 8% downside from the current price.
Don't just follow the ticker, dig into the data and build a conviction that's truly your own.
If you want to stress test your view on Xylem against other options, a quick pass through the Simply Wall St Screener can provide a few useful comparison points across quality, income and risk.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com